4 Einträge gefunden

1. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

   1. Goldschmidt, Hartmut
   2. Mai, Elias K
   3. Bertsch, Uta
   4. Fenk, Roland
   5. Nievergall, Eva
   6. Tichy, Diana
   7. Besemer, Britta

   2022 - Forschungsinformationssystem des UKE
2. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling

   1. Kaiser, Martin F
   2. Heider, Ulrike
   3. Mieth, Maren
   4. Zang, Chuanbing
   5. von Metzler, Ivana
   6. Sezer, Orhan

   2013 - Forschungsinformationssystem des UKE
3. The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.

   1. Lamottke, Britta
   2. Kaiser, Martin
   3. Mieth, Maren
   4. Heider, Ulrike
   5. Gao, Zhenhai
   6. Nikolova, Zariana
   7. Jensen, Michael R

   2012 - Forschungsinformationssystem des UKE
4. BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.

   1. Sterz, Jan
   2. Jakob, Christian
   3. Kuckelkorn, Ulrike
   4. Heider, Ulrike
   5. Mieth, Maren
   6. Kleeberg, Lorenz
   7. Kaiser, Martin

   2010 - Forschungsinformationssystem des UKE